Delivery Order SPE2DR25D9168-SPE2DR26FCRY6
- Not listed
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 17, 2026, for $19,246.77 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of JAKAFI 10 mg tablets (60-count units). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of...
- The Defense Logistics Agency issued a $50,883.68 delivery order to DMS Pharmaceutical Group Inc. on February 6, 2026, for JAKAFI 5 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a DLA-administered indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 11, 2026, for $12,589.11 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of Jakafi 20 mg tablets (60-count units). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense healthcare facilities worldwide. The contract has a $499.9 billion ceiling with an ultimate completion date of...
- The Defense Logistics Agency issued a $37,989.81 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on February 6, 2026, for supply of Jakafi 10 mg tablets under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations worldwide....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 3, 2026, for $12,582.95 (ceiling value) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of Jakafi 15 mg tablets (60-count). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products including branded and generic prescription drugs, over-the-counter medications,...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 12, 2026, for $25,326.56 (firm fixed price) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of Jakafi 10 mg tablets. PPV-G GEN V is the Defense Logistics Agency's indefinite delivery contract vehicle for pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, with a ceiling value of $18,516.41 for supply of JAKAFI 5 mg tablets (60 count) under its Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract. DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, IL. The order is firm fixed price with an ultimate completion date of February 10, 2026. PPV-G GEN V...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 11, 2026, for Jakafi 5 mg tablets (60-count units) with a ceiling value of $25,441.84, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business...
- The Defense Logistics Agency issued a $25,326.56 delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, for Jakafi 10 mg tablets under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 6, 2026, for $75,497.70 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of Jakafi 15 mg tablets (60-count units). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense military healthcare facilities worldwide. The order is firm fixed price with an ultimate completion date of February...
- SPE2DR25D9168Indefinite Delivery Contract
- SPE2DR25D9168-SPE2DR26FCRY6Delivery Order
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 10, 2026, with a ceiling value of $55,678.45, for supply of JAKAFI 10 mg tablets (60-count units) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products, branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense healthcare operations globally. Place of performance is Park Ridge, Illinois. Ultimate completion date is February 11, 2026. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler and holds a single-award IDC under PPV-G GEN V with a $499.999 billion ceiling and base period through December 31, 2036.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $55.7k | 2/9/26 |